Seattle genetics announces the approval of tukysa™ (tucatinib) in switzerland for the treatment of patients with metastatic her2-positive breast cancer

Seattle genetics, inc. (nasdaq:sgen) today announced that the swiss agency for therapeutic products (swissmedic) has granted approval for tukysa™ (tuc

AXDX Ratings Summary

AXDX Quant Ranking